Novel chronotherapeutic rectal aminophylline delivery system for therapy of asthma.
The aim of this study was to develop a new chronotherapeutic pharmaceutical preparation as a sustained-release suppository for prevention and therapeutic use against bronchial asthma in the early morning. Sustained-release hollow-type (SR-HT) suppositories using sodium alginate (Alg-Na), sodium polyacrylate (PANa) or polyacrylate-PANa co-polymer (PA-PANa) as gelling polymers (gel agent) were prepared and pharmaceutical characteristics of these suppositories were investigated. Type A SR-HT suppositories comprised a suppository shell prepared with oleaginous base and containing aminophylline only or aminophylline with Alg-Na or PANa in the cavity (hollow space). Type B SR-HT suppositories comprised a suppository shell prepared with oleaginous base and gel agent (30%), with aminophylline in the hollow space. In drug-release studies, the acrylate polymer-containing suppositories showed linearity of delayed release rate, providing significantly decreased the highest concentration of theophylline in plasma (C(max)) and delayed the time required to reach C(max) (t(max)) and the mean residence time (MRT) after rectal administrated in rabbits. In particular, suppositories containing PA-PANa maintained significantly higher theophylline concentrations than control suppositories at 12h after rectal administration. Furthermore, histopathological examination indicated that these suppositories using acrylate polymers did not result in rectal lesions. The SR-HT suppository, particularly using PA-PANa as a gel agent, may thus be useful against nocturnal symptoms of asthma. In this study, we confirmed new formulation of sustained-release suppository for chronotherapy of theophylline using oily base material in combination with polymer such as PA-PANa. The hollow-type suppository containing oleaginous base and hydrophilic polymer in the shell could be useful device for rectal administration of various drugs with prolongation of plasma concentration.
Shiohira
Hideo
H
Department of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida-Shi, Tokyo 194-8543, Japan.
Fujii
Makiko
M
Koizumi
Naoya
N
Kondoh
Masuo
M
Watanabe
Yoshiteru
Y
D000180:Acrylic Resins / Q000737:chemistry; D000285:Administration, Rectal; D000464:Alginates / Q000737:chemistry; D000628:Aminophylline / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019454:Chronotherapy / Q000379:methods; D003692:Delayed-Action Preparations; D005782:Gels; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D008297:Male; D011108:Polymers / Q000737:chemistry*; D011817:Rabbits; D013488:Suppositories; D013806:Theophylline / Q000493:pharmacokinetics
D000180:Acrylic Resins; D000464:Alginates; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D005782:Gels; D006603:Hexuronic Acids; D011108:Polymers; D013488:Suppositories; D000628:Aminophylline; C006903:carbopol 940; D020723:Glucuronic Acid; D013806:Theophylline